The fund overview for GMO E summarizes mandate, holdings profile, and risk characteristics. The fund has exposure to Mutual Fund Funds. The current allocation is approximately 21.0% equities, 58.0% bonds and 16.0% cash. It is classified under Intermediate Core-Plus Bond within the GMO family.
Methodology
Unless otherwise specified, data for Gmo E Plus is derived from fund disclosures (prospectus language, holdings reports, and periodic statements where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on instrument type. Gmo E Plus market data and reported NAV may reflect delayed updates. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We use public fund disclosures, holdings reports, and market data feeds with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Research Sources
Gmo E Plus may have reference inputs that incorporate holdings disclosures, category classification, and NAV-derived statistics where available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by:
Ellen Johnson, Member of Macroaxis Editorial Board
These listed companies frame GMO E's former industry context and operating niche. For a delisted instrument, comparable peers are more useful for sector reference than for direct trading signals or return forecasting.
This overview focuses on the additional market-friction and disclosure concerns attached to delisted securities. It focuses on venue risk, disclosure gaps, and the challenge of exiting a position efficiently. Investing in delisted funds can be risky, as the mutual fund is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.
The contribution of each position to portfolio variance is a function of weight and correlation. Portfolio-level transparency adds depth to allocation analysis.
GMO E information presented here supports broader research rather than acting as a stand-alone signal. GMO E analysis across multiple dimensions - risk, valuation, diversification - produces a more complete analytical picture. You can also try the
FinTech Suite module to use AI to screen and filter investment opportunities.
Gmo E Plus is no longer listed on a major exchange and may trade through OTC venues. Delisted securities typically carry elevated liquidity and reporting risk.